Background
==========

Hirschsprung disease (HSCR, OMIM 142623) is a congenital malformation characterized by the absence of intramural ganglion cells in the myenteric and submucosal plexuses along a variable portion of the distal intestine, due to a defect of craniocaudal migration of neuroblasts originated from the neural crest \[[@B1],[@B2]\]. HSCR presents an estimated incidence of 1/5000 live births, and has a non mendelian inheritance with reduced penetrance, variable expression and male predominance. Although familial forms exist, the vast majority of cases are sporadic. In addition, the disease can present as an isolated trait, although in a 30% of the cases it is associated with chromosomal abnormalities, neurodevelopment disorders and a variety of additional isolated anomalies and syndromes \[[@B2]\].

HSCR has a complex genetic aetiology with several genes being described as associated with isolated or syndromic forms. *RET*proto-oncogene is considered the major causal gene in HSCR and has been extensively studied in different HSCR series worldwide. Both traditional *RET*coding mutations and a common non-coding *RET*variant within a conserved enhancer-like sequence in intron 1, have been reported to be associated with a great proportion of HSCR cases \[[@B2]-[@B4]\]. Other genes associated with HSCR encode for receptors, ligands (especially those participating in the *RET*and *EDNRB*signaling transduction pathways), and transcriptional factors, such as *SOX10*and *PHOX2B*, among others, that are usually involved in the neural crest cell development and migration \[[@B2]\].

Interestingly, many recent reports point out the implications of altered gene dosage in diagnosis, prognosis and therapy in different human diseases \[[@B5]\]. Nonetheless, it does not seem to be apparently the case of HSCR, with the current data supporting a predominance of missense/nonsense mutations, although small deletions/insertions have been occasionally observed (Human Gene Mutation Database of the Institute of Medical Genetics in Cardiff, <http://www.hgmd.cf.ac.uk/ac/index.php>). In fact, no duplications and only one gross deletion affecting the entire sequence of *RET*have been reported \[[@B6],[@B7]\]. To date, only 2 studies have been reported investigating gene dosages anomalies in HSCR patients based on MLPA technique (Multiple Ligation-dependent Probe Amplification) \[[@B8],[@B9]\], which has an optimal performance to detect alterations of gene dosages \[[@B10]\]. Both of them used MLPA MRC-Holland commercial kit for HSCR, that analyses a limited number of genes (*RET, ZEB2, EDN3*and *GDNF*), and revealed no CNVs associated to HSCR in those genes \[[@B8],[@B9]\]. In additions we have performed a *SOX10*deletion screening on our HSCR patients \[[@B11]\] based on a previously reported QMF-PCR method (Quantitative Multiplex Fluorescent PCR), obtaining negative results \[[@B12]\]. Nevertheless, studies in other \"HSCR genes\" are necessary to rule out the potential implication CNVs in the pathogenesis of HSCR.

In the present study we have analyzed the presence of CNVs for *EDNRB, NRTN, GFRA1 and PHOX2B*in our patient series, using self-designed MLPA probes, as no commercial kit is available for those genes, and none of them has been previously evaluated for mid-size deletions/duplications using a high-throughput technique. The present self-design set of probes for MLPA analysis, together with the available MLPA commercial kit for HSCR, would lead to the complete analysis of CNVs within coding region of the most prevalent genes in HSCR.

Methods
=======

Patients and Control Subjects
-----------------------------

In this study, a total of 208 HSCR patients have been included (22% female, 77% male). 188 out of the 208 patients were sporadic cases, while 20 were familial cases belonging to 13 different families. In addition, 6 of those patients presented with associated Down\'s syndrome, and 1 presented with Waarbenburg\'s Syndrome type 4. In order to define the exact HSCR phenotype in our patients, we have used the criteria recommended by Chakravarti and Lyonnett \[[@B1]\]. Following these criteria, 137 cases were catalogued as short-segment HSCR (S-HSCR, 81%), 21 cases as long-segment (L-HSCR, 12%), and 12 cases presented as total colonic aganglionosis (TCA, 7%). Data were not available for the remaining 38 cases.

We have also used a group of 100 controls comprising unselected, unrelated, race, age, and sex-matched individuals. All of them were healthy voluntary donors, who came to the Hospital for other reasons and did not present any symptom suggestive of HSCR.

Genomic DNA was extracted according to standard protocols and an informed consent was obtained from all the participants for clinical and molecular genetic studies. The study conformed to the tenets of the declaration of Helsinki and was approved by the Hospitales Universitarios Virgen del Rocío IRB.

MLPA analysis
-------------

Gene dosage variations on *EDNRB, GFRA1, NRTN*and *PHOX2B*were analysed by MLPA technology. The selection of the genes was based on their implication in ENS development and HSCR disease \[[@B13]\]. More specifically, we have selected *EDNRB*, the second major gene for HSCR, which has a considerably higher mutational incidence than *EDN3*, *GDNF*or *ZEB2*\[[@B2]\], included in the commercial kit. Since *RET*and *GDNF*are already included in the commercial MLPA kit for HSCR, we decided to include *NRTN*and *GFRA1*, as they are implicated in the same signaling pathway and have been previously associated to HSCR \[[@B14],[@B15]\]. In addition and due to the implication of *PHOX2B*deletions in human pathologies and syndromes than frequently present with HSCR (CCHS) \[[@B16]\], we have also included this gene in the present study. Following MRC-Holland recommendations, we designed 31 sets of probes to detect deletions and duplications in one or more exons of these 4 genes (Table [1](#T1){ref-type="table"}). In addition, we designed 3 control fragments hybridizing to different genome regions, that have never been associated with HSCR before and have been reported to contain no CNVs. Probes and EK-1 kits were supplied by Sigma (Sigma-Aldrich, St. Louise, MO) and MRC-Holland (MRC-Holland, Amsterdam, Netherlands) respectively.

###### 

Self-designed MLPA probes used in the molecular analysis of *EDNRB, GFRa1, NRTN*and *PHOX2B*CNVs of 208 HSCR patients.

                    Exon           Probe Oligo Sequence\*                                                        bp
  ----------------- -------------- ----------------------------------------------------------------------------- -----
  EDNRB             EDNRBen1Δ3     LPO TCTGGCGGTGATTGATGGGAAG                                                    100
                                   RPO GGATGAATGAATAAAAGTACTTGTCTGATGGCACCC                                      
                    EDNRBex1       LPO TCTACAAGAACAAGTGCATGCGAAACG                                               112
                                   RPO GTCCCAATATCTTGATCGCCAGCTTGCCATCAATCGCCATTCGA                              
                    EDNRBex2       LPO GGCAGAGGACTGGCCATTTGGAG                                                   90
                                   RPO CTGAGATGTGTAAGCTGGTGCCTTT                                                 
                    EDNRBex3       LPO CGACAGCAGTAGAAATTGTTTTGATTTGGGTG                                          128
                                   RPO GTCTCTGTGGTTCTGGCTGTCCCTGAAGAGGTTTTGTGTACGGACCTAAAGTTC                    
                    EDNRBex4       LPO TGGCATGCAGATTGCTTTAAATGATCAC                                              113
                                   RPO CTAAAGCAGGTAAGAAAATACAAATATTGAGAGGGACACGGCG                               
                    EDNRBex5       LPO GTGGCCAAAACCGTCTTTTGCCTG                                                  93
                                   RPO GTCCTTGTCTTTGCCCTCTGCTGGCTT                                               
                    EDNRBex6       LPO CGATGCTATTCACATAACCCAATTGCTCTGTATTTGGTGAG                                 130
                                   RPO GTGAGCAAAAGATTCAAAAACTGCTCTTGGAGGAAGTCGAGGAGTAC                           
                    EDNRBex7       LPO GCAGTCGTGCTTAAAGTTCAAAG                                                   99
                                   RPO CTAATGATCACGGATATGACAACTTTGCTGAGTG                                        
                                                                                                                 
  GFRα1             GFRa1ex1       LPO CCTAGCGCAGATAAAGTGAGCCCGGAAAG                                             135
                                   RPO GGAAGGAGGGGGCGGGGACACCATTGCTATAGACGTAGCTGTGAGTACCAACCGAATAGCAATC          
                    GFRa1ex2       LPO CAACGACTAGAGAGGCACCATGTTCCTGGCGACC                                        127
                                   RPO GATGGAGCTGAACTTTGGGCGGCCAGTGACTGCCTTGAAGGTCTCACGGCT                       
                    GFRa1ex3       LPO GGAGAAGAACTGCCTGCGCATTTACTGGAG                                            96
                                   RPO CATGTACCAGAGCCTGCAGGGTAC                                                  
                    GFRa1ex4       LPO GGAGGATTCCCCATATGAACCAGTTAACAG                                            100
                                   RPO CAGATTGTCAGATATATTCCGGGTGGTC                                              
                    GFRa1ex5       LPO CAGGCACTTGAGGATTTCCCAGGTAGGACCCTCTAGTTGCAG                                131
                                   RPO GAAAACAAGGTCAGGGCTGCCACTGGTTCTATAATACAATGGAGACG                           
                    GFRa1ex6       LPO GGAACAACTGCCTGGATGCAGCGAAGGCCTG                                           108
                                   RPO CAACCTCGACGACATTTGCAAGAAGTACCCGGTAT                                       
                    GFRa1ex7       LPO TGCCAGCCAGAGTCAAGGTCTGTCAG                                                95
                                   RPO CAGCTGTCTAAAGGAAAACTACGCTGA                                               
                    GFRa1ex8       LPO CCATACATCACCGCATTCTCGCAGAAGAGCCTCAGTGTGGCCCCATGGTGTGACTG                  132
                                   RPO CAGCAACAGTGGGAACGACCTAGAAGAGTGCTTG                                        
                    GFRa1ex9a      LPO GAGGAAGTTCAATGGCTCCGATGTGACCGTGTGGCAG                                     108
                                   RPO CCAGCCTTCCCAGTACAGACCACCACTGC                                             
                    GFRa1ex9b      LPO CCAATTGACCACCTATGGGCCCAGTCC                                               140
                                   RPO CCAGTCAGGTCAAAGAAGAGGGTTTACGTAGACCTCAGTTCACTGGAGTCTGTCGTTTGCTCTATACTCAC   
                    GFRa1ex9c      LPO GGTTCAGGCAACACAGAGACAAAG                                                  91
                                   RPO CATCTTCAGGGGGAGCAGGTAGAGG                                                 
                    GFRa1ex9d      LPO GTGTCCACTTGTTTTACGCAG                                                     108
                                   RPO CTGACTTTACTGGACATTATTCAGACCAGTGGTTGGGTGCGCTCG                             
                    GFRa1ex10      LPO GCTGAAATCCAATGTGTCGGGCAATACACAC                                           112
                                   RPO CTCTGTATTTCCAATGTAAGTATGGGCGTGGACTCGCAT                                   
                    GFRa1ex11      LPO CCAAACTGTGCGCGTGTCGATAAGGTTCCGTTCCCGCCCACTGCTGGTCCTGGTGGTAACC             136
                                   RPO GCTCTGTCCACCCTATTATCTTTAACAGAAACA                                         
                                                                                                                 
  NRTN              NRTNex1        LPO CGTTCAAAGTCAAAGGCCCCACACTGAGTC                                            136
                                   RPO CTGGCCCAGCGCCCTGTGCCCGTTGGCTGACGAGAAGTACGGAATCGAATCTATAGTGACCTAT          
                    NRTNex2        LPO CGAATTAGAGATTTAACTTCCTCCCCTCGCAGACCGTGCACTC                               139
                                   RPO CTGCAGGGGGCCCCGGATGCGATGGAGCTGTTAATACGACTCACTATAGGAGTA                    
                                                                                                                 
  PHOX2B            PHOX2B5\'UTR   LPO CTTAAATCATGGGGCCACTGAAGTC                                                 92
                                   RPO CACACACTGCTCGCTCCTTTGT                                                    
                    PHOX2Bex1A     LPO CCTCAATTCCTCTGCCTACGAGTC                                                  88
                                   RPO CTGTATGGCTGGGATGGACACC                                                    
                    PHOX2Bex1B     LPO CCAGTGGCTTCCAGTATAACCCGATAAGGAC                                           96
                                   RPO CACTTTTGGGGCCACGTCCGGCT                                                   
                    PHOX2Bex2      LPO CTGTCATACTCTAGTTCCTTACAAACTCTTCAC                                         108
                                   RPO GGACCACGGCGGCCTCAACGATGCAAGCGACAT                                         
                    PHOX2Bex3A     LPO TCTTCTTTCTCCCCCTGCTTCACCGTCTCTC                                           112
                                   RPO CTTCCGTCTTGGGCCAGGTGTGGTTCCAGAATTTACTAA                                   
                    PHOX2Bex3B     LPO CGTCCTATCTTCGCTCCAAAGACCCAACG                                             100
                                   RPO GTGCCAAAGCCGCCTTAGTGAAGAGCAGT                                             
                    PHOX2B3\'UTR   LPO CTTTTTCATTGAGGGCCTAAAGTAATCGCGCTAAGAATAAAG                                126
                                   RPO GGAAAACGGCGTCGCCCTCATTTGCAAACTGTGCGGGTGTCG                                
                                                                                                                 
  Reference genes   TOR1A          LPO GCACCGGCAAAAATTTCGTCAGCAAGATCAT                                           104
                                   RPO CGCAGAGAATATTTACGAGGGTGGTCTGAAC                                           
                    EPO            LPO GCCTCAGCTGCTCCACTCCGAACAATCACTG                                           117
                                   RPO CTGACACTTTCCGCAAACTCTTCCGAGTCTAGATAGTTCCAACAA                             
                    SS18           LPO CGACAGCATTACGAAGCACAGCAGCCACCTATGGGAATGATG                                122
                                   RPO GGTCAAGTTAACCAAGGCAATCATATGATGCGATATGC                                    

\*Sequences do not included the universal primers located al the 5\' end of LPO and 3\' end of RPO.

Capillary electrophoresis analysis was performed using an ABI PRISM^®^3730 DNA analyzer (Applied Biosystems, Foster City, CA) and for data analysis we used GeneMarker v 1.75 (Softgenetics L.L.C, State College, PA). We normalized the samples by peak height comparing patients with 10 controls. These 10 control individuals had been confirmed to have no duplications or deletions in the studied genes, by a previous analysis using Affymetrix Genome-Wide Human SNP Arrays 6.0. In addition as a positive control we included a patient harbouring a *GFRA1*deletion in heterozygosis (patient HSCR-5, presenting with TCA-total colonic aganglionosis), which had been previously characterized by southern blot and lost of heterozygosity of STRs \[[@B15]\]. This individual not only was useful as positive control, but also confirmed the validity of our method to detect deletions in the genes analysed. Following manufacturer recommendations, dosage quotients under 0.5 or over 1.3 were considered as indicating potential deletions or duplications respectively, and were confirmed in 3 independent assays.

Results
=======

With the aim to analyse anomalies in the gene dosage of several genes described as associated to HSCR (*EDNRB, GFRA1, NRTN*and *PHOX2B*), but never previously analyzed by MLPA, we designed specific synthetic MLPA D-probes, following MRC-Holland recommendations. The hybridization, ligation and amplification of the MLPA probes were performed in 4 different probemixes of 8-10 probes each, together with the 3 control probes. Signal peaks height of the amplified products observed after electrophoresis, were as homogeneous as expected for self-designed probes, and peak normalization was successfully fulfilled between the patient samples and controls in all the probemixes tested.

After the validation of our probes, we screened a total of 208 HSCR patients and found a deletion in *GFRA1*gene (c.(?-555)\_431+?del; Figure [1](#F1){ref-type="fig"}) that affects exons 1a, 2a, 3 and 4 in isoform NM_005264 and exons 2b, 3 and 4 in isoform NM_145793. This deletion was detected in a heterozygous state, in a sporadic and isolated male HSCR patient presenting with short-segment HSCR (patient HSCR-115), and was not found in 100 control individuals tested. This deletion was inherited by his unaffected father, and was found to be absent in other healthy members of the family. There are 2 CNVs described for *GFRA1*gene annotated in the Database of Genomics Variants <http://projects.tcag.ca>, Variant_48418 and Variant_48004. The first variant is a 2.5Kb deletion located in the 3\' untranslated region of the gene, while the other consisted on a 36 Kb deletion the genomic region containing exons 7, 8 and 9 of *GFRA1*. Therefore, the available data support that we are describing a novel deletion. Interestingly, this is the second time this deletion has been found in our HSCR patient series, in a patient not related with the one previously reported \[Figure [1](#F1){ref-type="fig"}; 15\].

![**MLPA profiles for control individuals (red) and for the HSCR patient (blue)**. Two different probes-mixes are shown (A and C mix 1; B and D mix 2). For those HSCR patients (A and B, HSCR-115; C and D, HSCR-5), it was observed a decrease for the dosage of *GFRA1*exons 1, 2, 3 and 4, highlighted in red boxes and by arrows.](1471-2350-11-71-1){#F1}

In order to preliminarily examine the potential damaging effect of this deletion on *GFRA1*expression and functionality, we used InterProScan and AlternativeSplicing tools from EBI and Transec from EMBOSS. We verified that the critical translation initiation signal in the gene was abolished; subsequently no wild-type (WT) protein was expected to be expressed from the deleted copy of the gene. In adition, we checked *in silico*whether the deleted allele could produce any protein with similar functional capacity as GFRα1. We found that an alternative peptide could be translated from deleted isoform NM_005264 with the same carboxyl-terminus aminoacidic sequence. This putative protein would maintain one of the 3 GDNF/GAS1 domains in the WT protein, but would also lack the localization signal in the N-terminal region. Although this deletion is well refined in its 3\' end, we failed to establish the boundaries in the 5\' end where all transcription and translation signals are located. Therefore it seems unlikely that the aberrant protein could be expressed, and in that case it would have a very limited, or even null, functionality.

Discussion
==========

HSCR has a complex genetic aetiology and point mutations in several genes have been reported to be implicated in a portion of isolated and syndromic HSCR forms \[[@B2]\]. It is tempting to speculate that other genetic events different from point mutation, such as CNVs, have a functional role in the pathogenesis of HSCR. Very little is known in this field for HSCR since typical screening methods based in conventional PCR are only able to detect small deletions/duplications (a few base pairs), and cytogenetic techniques can exclusively detect alterations in the order of megabases. Those techniques are neither powerful nor adequate to detect CNVs \[[@B10]\], so that those types of rearrangements would be missed. In this way, it would be possible that such mid-size deletions/duplications in several HSCR genes have been underreported. In addition, traditional techniques used to detect mid-size deletions/duplications, such as southern blot, are expensive, time consuming and not suitable for high-throughput results. For this reason we planned to perform CNVs screening in a large series of HSCR patients using MLPA technology, which can be performed in a large number of individuals within a short period time, in order to determine if it is a reliable technique suitable for a routine CNVs screening. Despite the negative results previously reported for HSCR MLPA commercial kit \[[@B8],[@B9]\], we have obtained positive results with the finding of a deletion affecting the 4 first exons in *GFRA1*. This deletion was previously identified in a sporadic HSCR patient, but its actual implication in the pathogenesis of this disease remained unknown \[[@B15]\]. The finding of the same deletion in an independent patient with the same phenotype and its absence in the control population, support that this deletion at the *GFRA1 locus*is a mutational event potentially related to HSCR. In addition, the implementation of MLPA technique for midsize deletion detection leads us to refine the deleted region at *GFRA1*locus. The protein GFRα1 is one of the four co-receptors of the RET tyrosine kinase receptor. The binding of RET to GFRα1 is required for the specific recruitment of GDNF and the subsequent phosphorylation of RET. Therefore, the presence of such a deletion in GFRα1 would avoid the expression of the protein, presumably preventing RET phosphorylation and affecting the correct development of the ENS. The presence of this mutation in unaffected members of the family suggest that it could be necessary but not sufficient to produce the phenotype, and additional unidentified genetic events might be acting in this HSCR patient. In this sense, no point coding mutations were detected in this patient, or in the previously described patient harbouring the same deletion, in other HSCR-related genes tested such as *RET*, *GDNF, NRTN, PSPN, ARTN, EDNRB*, *EDN3*, *NTF3, NTRK3, SOX10*or *PHOX2B*. The present results indicate that CNVs are not a common molecular cause of HSCR, although they should be taken into account for further studies.

Conclutions
===========

One of our goals was to provide a simple, reliable, economic and fast method for CNVs screening in HSCR related genes, and the present study has successfully validated the self-designed MPLA probes for CNVs analysis. The design and validation of MLPA probes for additional genes represent an implementation for a technique that was restricted to the commercial production. In this sense, the present design, together with the commercial MLPA kit for HSCR, allows the complete analysis of CNVs in the coding region of the most prevalent genes for HSCR. In addition, the presence of a *GFRA1*deletion that seems to impair protein function, in an unrelated HSCR patient supports and confirms the idea that this specific deletion might participate in the development of HSCR. Despite the fact that CNVs seems to be an uncommon susceptibility factor leading to this disease, our results point out the importance of taking into account those molecular events in HSCR studies from now on, at least in *GFRA1*gene. Further screening of CNVs in additional series of patients would be necessary in order to completely address its real implications in the pathogenesis of HSCR.
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